4//SEC Filing
OrbiMed Israel GP Ltd. 4
Accession 0000947871-21-000350
CIK 0001534248other
Filed
Mar 17, 8:00 PM ET
Accepted
Mar 18, 9:59 PM ET
Size
11.1 KB
Accession
0000947871-21-000350
Insider Transaction Report
Form 4
Transactions
- Award
Warrants (Right to Buy)
2021-03-16+28,817→ 28,817 total(indirect: See Footnotes)Exercise: $17.35Exp: 2026-03-16→ American Depository Shares (28,817 underlying) - Award
American Depository Shares
2021-03-16$17.35/sh+288,170$4,999,750→ 2,578,174 total(indirect: See Footnotes)
OrbiMed Israel GP Ltd.
10% Owner
Transactions
- Award
American Depository Shares
2021-03-16$17.35/sh+288,170$4,999,750→ 2,578,174 total(indirect: See Footnotes) - Award
Warrants (Right to Buy)
2021-03-16+28,817→ 28,817 total(indirect: See Footnotes)Exercise: $17.35Exp: 2026-03-16→ American Depository Shares (28,817 underlying)
Footnotes (4)
- [F1]Each ADS represents twenty (20) Ordinary Shares of the Issuer. These ADSs were purchased in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended.
- [F2]These shares of the Issuer's common stock are held of record by OrbiMed Israel Partners Limited Partnership ("OIP"). OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund") is the general partner of OIP, and OrbiMed Israel GP Ltd. ("OrbiMed Israel GP") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed BioFund and OrbiMed Israel GP may be deemed to have voting and investment power with respect to the shares held directly by OIP noted above and, as a result, may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Israel GP exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan T. Silverstein, Nissim Darvish, Anat Naschitz, and Erez Chimovits, each of whom disclaims beneficial ownership of the shares held by OIP.
- [F3]This report is being jointly filed by OrbiMed BioFund. and OrbiMed Israel GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons are a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
- [F4]The warrants are held of record by OIP and are immediately exercisable.
Documents
Issuer
Chemomab Therapeutics Ltd.
CIK 0001534248
Entity typeother
IncorporatedIsrael
Related Parties
1- filerCIK 0001569590
Filing Metadata
- Form type
- 4
- Filed
- Mar 17, 8:00 PM ET
- Accepted
- Mar 18, 9:59 PM ET
- Size
- 11.1 KB